A5114859498- Lung Cancer Treatments and Mutations
- Lung Cancer Research Studies
- RNA modifications and cancer
- Colorectal Cancer Treatments and Studies
- Cancer Genomics and Diagnostics
- Gastric Cancer Management and Outcomes
- Lung Cancer Diagnosis and Treatment
- DNA Repair Mechanisms
- Cancer Diagnosis and Treatment
- Synthesis and biological activity
- Radiomics and Machine Learning in Medical Imaging
- Cancer Treatment and Pharmacology
- Sarcoma Diagnosis and Treatment
- Neuroendocrine Tumor Research Advances
- Cancer Immunotherapy and Biomarkers
- Economic and Financial Impacts of Cancer
- Cancer Mechanisms and Therapy
- Metastasis and carcinoma case studies
- Soft tissue tumors and treatment
- Cancer therapeutics and mechanisms
- Neuroblastoma Research and Treatments
- Ethics in Clinical Research
- Bone Tumor Diagnosis and Treatments
- Pancreatic and Hepatic Oncology Research
- Advanced Breast Cancer Therapies
Universiti Malaysia Perlis
2025
University of Virginia
2022-2024
Virginia Cancer Institute
2022-2024
University of Fairfax
2023
Augusta University
2021-2022
Augusta University Health
2019-2022
Palmetto Hematology Oncology
2022
University of Cincinnati
2008-2019
University of Cincinnati Medical Center
2017
•Dynamic changes in ctDNA can be used to predict tumor response therapeutic regimens oncology.•LB-RECIST have been proposed and the context of clinical trials.•Several challenges exist for applicability need addressed a more standardized approach. Current evaluation treatment solid tumors depends on dynamic diameters as measured by imaging. However, these only detected when there are enough macroscopic volume, which limits usability radiological criteria evaluating earlier stages disease...
Abstract KRAS is the most commonly mutated oncogene in NSCLC and development of direct inhibitors has renewed interest this molecular variant. Different mutations may represent a unique biologic context with different prognostic therapeutic impact. We sought to characterize genomic landscapes advanced, KRAS-mutated non–small cell lung cancer (NSCLC) large national cohort help guide future development. Molecular profiles 17,095 specimens were obtained using DNA next-generation sequencing 592...
Introduction: Parathyroid carcinoma (PC) is an extremely rare entity, with a frequency of 0.005% all malignancies. Most data related to this disease are limited case series and few database studies. We present large study that aims investigate the demographic, clinical, pathological factors, prognosis, survival PC. Methods: Data parathyroid were extracted from Surveillance, Epidemiology, End Results (SEER) diagnosed between 1975 2016. Results: PC had slightly higher incidence in men (52.2%,...
Introduction: Gastrointestinal stromal tumors (GISTs) are the most common mesenchymal neoplasm of gastrointestinal (GI) system. Most GISTs originate from interstitial cells Cajal (ICC), pacemaker cell situated between circular and longitudinal layers muscularis propria along GI tract. In this population-based study using SEER database, we sought to identify demographic, clinical, pathologic factors that affect prognosis survival patients with neoplasm. Molecular genetic advances, current...
Background: Salivary gland neoplasms are uncommon in both pediatric and adult populations. Mucoepidermoid carcinoma (MEC) is one of the most common salivary tumors usually presents with atypical clinical features. This study sought to evaluate demographic factors affecting outcomes adults populations MEC that could be used risk stratification for treatment selection trial enrollment. Methods: Data on 4507 patients were extracted from Surveillance Epidemiology End Result (SEER) database...
Gold nanoparticles (AuNPs) have indeed been extensively researched in biological and photothermal therapy applications recent years. This study aims to enhance the sensitivity of biosensors for early detection ovarian cancer biomarkers by investigating efficacy DES-mediated surface functionalization AuNPs. Additionally, impact DES on stability dispersion AuNPs SiO2 support is assessed optimize sensor performance. A simple synthesis method efficient amine silicon dioxide (SiO2) incorporate...
Primary peritoneal mesothelioma (PPM) is a rare and aggressive tumor arising from the visceral parietal peritoneum. The diagnosis treatment of PPM are often delayed because non-specific clinical presentation, prognosis worse. current study investigated demographic, clinical, pathological factors affecting patient survival in PPM. Demographic data 1998 patients with were extracted Surveillance Epidemiology End Results (SEER) database (1975-2016). chi-square test, paired t-test, multivariate...
Src is overexpressed in various cancers, including 27% of non-small cell lung cancer NSCLC, and correlated with poor clinical outcomes. We hypothesize that kinase inhibitors, Bosutinib, may exhibit synergy combination the antifolate drug pemetrexed. In this Phase I, dose-escalation, safety, maximum tolerated dose (MTD)-determining study, 14 patients advanced metastatic solid tumors had progressed on “standard care” chemotherapy were enrolled a 3 + escalation study. Oral Bosutinib was...
Primary lung cancer is the most common cause of cancer-related mortality in United States (US). Approximately 90% cancers are associated with smoking and use other tobacco products. Based on histology, divided into small-cell carcinomas (SCLCs) non-small-cell (NSCLCs). Most SCLCs pure subtype, while rare combined contain elements both morphologies. This study sought to evaluate demographics, clinical factors, molecular abnormalities, treatment approaches, survival outcomes SCLC NSCLCs.Data...
Lung cancer remains a leading cause of cancer-related mortality globally and presents significant challenges in Egypt. In 2023, the first annual meeting Thoracic Oncology Multidisciplinary Faculty, organized by Egyptian Cancer Research Network Society Respiratory Neoplasms, was held Cairo, The aimed to address gaps lung management across Egypt broader Middle East North Africa region. discussions focused on posed NSCLC SCLC emphasized need for enhanced prevention, early detection, treatment...
The phase II ABOUND.PS2 study (NCT02289456) assessed safety/tolerability of a first-line modified nab-paclitaxel/carboplatin regimen for patients with advanced non-small cell lung cancer (NSCLC) and Eastern Cooperative Oncology Group (ECOG) performance status (PS) 2.Chemotherapy-naive stage IIIB/IV NSCLC ECOG PS 2 received four cycles nab-paclitaxel 100 mg/m2 days 1 8 plus carboplatin area under the curve 5 day q3w (induction). Patients without progression monotherapy (100 q3w) until...
This study aim was to determine the efficacy and safety of combination Gemcitabine 1000mg/m2 day 1 & 8 Irinotecan 100 mg/m2 with escalating dose thalidomide in chemonaive patients advanced non-small cell lung cancer. Among 20 who met eligibility criteria received treatment, two (10%) experienced partial response 14 (70%) stable disease. The median time disease progression 4 months (95% CI: 2.8–6.6). year 2 survival rates were 36% 27%, respectively. is active NSCLC manageable toxicity profile.
Background: Pulmonary sarcomatoid carcinoma (PSC) is a rare subtype of non-small cell lung cancer (NSCLC) with an aggressive clinical nature and poor prognosis. With novel targeted therapeutics being developed, new ways to effectively treat PSC are emerging. In this study, we analyze demographics, tumor characteristics, treatment modalities, outcomes genetic mutations in PSC. Methods: Data from the Surveillance, Epidemiology, End Results (SEER) database were reviewed cases pulmonary 2000...
Malignant peripheral nerve sheath tumors (MPNSTs) are growths that arise in conjunction with a and believed to originate from neural crest cells. These can sporadically but often associated the cancer-predisposing genetic condition, neurofibromatosis type 1 (NF-1). The clinical presentation of an enlarging mass, pain, paresthesias, neurologic deficits mirror other soft tissue sarcomas. Thus, suspicion should remain high for MPNST when this aggregation symptoms arises, particularly those...
Lung cancer is the leading cause of cancer-related deaths. Surgery remains best option to treat lung when feasible. However, many cases are diagnosed beyond initial stages. There has been tremendous progress in treatment over last few years. Studies have shown that biomarker-driven targeted therapies lead better outcomes. Due technical difficulties and significant procedural risk associated with repeated tissue biopsies, analysis tumor constituents circulating blood, such as DNA (ctDNA)...
Patients with advanced non-small cell lung cancer (NSCLC) have no curative treatment options; therefore, improving their quality of life (QOL) is an important goal. Gefitinib, epidermal growth factor receptor (EGFR) inhibitor, a safe oral agent that may be benefit to specific population NSCLC.A Phase II clinical trial included chemonaïve patients NSCLC and poor performance status (PS). Response rate, progression-free survival, overall QOL using the Functional Assessment Cancer Therapy - Lung...
Introduction Performance status (PS) is the only known clinical predictor of outcome in patients with advanced non-small-cell lung cancer (NSCLC), although pharmacogenomic markers may also correlate outcome. The aim our study was to and measures overall survival. Methods This an IRB approved, retrospective which medical records 50 NSCLC from 1998–2008 were reviewed, gender, race, PS, chemotherapy regimens documented. Stromal expression (VEGFR, ERCC1, 14-3-3σ, pAKT, PTEN) measured. Clinical...